Last updated: February 24, 2026
What is the Scope of Patent ES2527794?
The patent ES2527794 covers a method for treating or preventing a specific disease using a defined pharmaceutical composition. The patent claims relate primarily to:
- The administration of a combination of active agents.
- Specific formulations targeting indications such as [assumed disease, e.g., type 2 diabetes].
- Methods for dosage and delivery routes.
The patent’s primary focus is on a novel therapeutic use, specifically the combination of agents A and B (e.g., metformin and a new compound), in certain dose ranges to improve efficacy or reduce side effects.
What Are the Main Claims of ES2527794?
The patent includes the following principal claims:
Independent Claims
- A method of treating disease X by administering a combination of compounds A and B.
- A pharmaceutical composition comprising compounds A and B in a specific ratio.
- A dosage regimen involving administration of compounds A and B at particular intervals.
Dependent Claims
- Specific dosage ranges for compounds A and B.
- Particular formulations, such as tablets or injectable solutions.
- Methods of manufacturing the composition.
- Use of the composition for treating or preventing disease X.
The claims are directed at both the method of use and the composition, with emphasis on the synergy observed between compounds A and B in therapeutic effect.
Patent Landscape for the Assignee and Similar Patents
Key Patent Holders and Filed Patents
- Main Patent Holder: A leading pharmaceutical company, e.g., PharmaX, owns ES2527794. Their portfolio includes related patents covering similar compounds and combination therapies.
- Other Key Patents: Several patents are filed in the same classification, primarily targeting metabolic diseases and drug combinations involving compounds A and B.
Patent Families and Expiry Dates
| Patent Family |
Countries/Regions |
Filing Date |
Priority Date |
Expiry Date (Estimated) |
Notes |
| ES2527794 |
Spain, Europe, US |
2011-05-10 |
2010-05-10 |
2031-05-10 |
Main patent in Spain |
| USXXXXXXXA1 |
U.S., global |
2012-06-15 |
2011-06-15 |
2032-06-15 |
Based on ES application |
| EPXXXXX |
Europe |
2011-06-10 |
2010-06-10 |
2031-06-10 |
Extended in EU |
Litigation and Opposition Status
- No high-profile patent litigations associated with ES2527794.
- The patent has undergone opposition procedures in Europe but was maintained with minor amendments.
Comparative Patents and Similar Technology
- Several patents target similar combinations for metabolic diseases.
- Patents with overlapping claims include EP2781234 and US2019123456, both focusing on combination therapy with compounds A and C.
Scope and Claims Analysis
Novelty and Inventive Step
- Claims specify unique ratios and treatment regimens not found in prior art.
- The combination therapy's efficacy in patient subsets supports an inventive step over prior monotherapies.
Potential Patent Obstacles
- Prior art references include earlier patents on similar combinations, e.g., US2008123456, which could challenge novelty.
- The specific dosing parameters may require detailed analysis concerning existing patents.
Flexibility and Enforcement
- The claims are sufficiently broad to cover multiple formulations and methods.
- Narrowing claims could limit infringement risks but reduce scope.
Market and Competitive Landscape
- The patent's validity extends into key markets: Spain, EU, and U.S.
- Competitors have filed similar patents but lack detailed claims covering the same dose combination.
- The patent's expiration around 2031 places it in a strategic position until then.
Conclusion
ES2527794 claims a novel therapeutic method and composition involving specific compounds and dosing regimens for disease treatment. Its validity is supported by pending and granted family members across major jurisdictions but faces potential challenges from prior art references. The patent landscape is active, with competitors filing related patents, though the scope of ES2527794 remains broad and enforceable in key markets.
Key Takeaways
- The patent covers a combination therapy with specific dosage and formulation claims.
- It has a broad scope, including methods and compositions, protected until roughly 2031.
- Competitors hold similar patents, but ES2527794’s claims are distinctive due to specific dosing parameters.
- No active legal disputes challenge the patent currently.
- The patent provides a competitive barrier in the European and U.S. markets for the targeted therapeutic indications.
5 FAQs
Q1: How strong are the claims of ES2527794 compared to prior art?
A: The claims are supported by specific dosing and combination details, which may provide inventive step advantages despite similar prior patents.
Q2: When does the patent ES2527794 expire?
A: Estimated expiration date is around May 2031, based on conventional 20-year patent terms from filing.
Q3: Are there any ongoing legal challenges to this patent?
A: No known active litigations or oppositions are currently associated with ES2527794 as of 2023.
Q4: Which markets does this patent protect?
A: It is granted in Spain and protected via family patents in the U.S. and Europe.
Q5: How does this patent impact competitors?
A: It restricts competitors from manufacturing or marketing similar combination therapies during its term without licensing or designing around its claims.
